You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 125 No. 7, July 2007 TABLE OF CONTENTS
  Archives
  •  Online Features
  Socioeconomics and Health Services
 This Article
 •Full text
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on Web of Science (2)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Aging/ Geriatrics
 •Macular Degeneration
 •Quality of Life
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Health-Related Quality of Life and Utility in Patients With Age-Related Macular Degeneration

José-Alain Sahel, MD; Francesco Bandello, MD; Albert Augustin, MD; Frédérique Maurel, MS; Cristina Negrini, MSC; Gilles H. Berdeaux, MD; for the MICMAC Study Group

Arch Ophthalmol. 2007;125(7):945-951.

Objective  To assess the impact of best-eye and worst-eye visual acuity (BEVA and WEVA, respectively) on health-related quality of life and utility in patients with wet age-related macular degeneration.

Design  This cross-sectional, prospective, observational, multicenter study was performed in France, Germany, and Italy. Patients were stratified into 4 severity groups (BEVA, 20/40; WEVA, 20/200). Patients completed the National Eye Institute 25-Item Visual Function Questionnaire, the Macular Disease Quality of Life Scale, and the Health Utility Index 3. Analysis of variance was used to adjust for age, sex, and country.

Results  Patients (N = 360) were mainly female (59.6%), with a mean age of 77 years and mean time since age-related macular degeneration diagnosis of 2.3 years. Health Utility Index 3 scores decreased with VA severity from 0.62 to 0.39. The National Eye Institute 25-Item Visual Function Questionnaire global score decreased with VA severity from 67.0 to 40.7 and was related to the BEVA (P < .001) and WEVA (P = .03). Corresponding changes were observed on the general vision, distance vision, driving, and mental health dimensions. The average weighted impact score on the Macular Disease Quality of Life varied from –4.6 to –2.6, decreasing with VA severity. Both eyes contributed to the average weighted impact score.

Conclusion  The BEVA and WEVAs influenced vision-related quality of life independently, as measured by the National Eye Institute 25-Item Visual Function Questionnaire and Macular Disease Quality of Life Scale.


Author Affiliations: Department IV, Hôpital des XV-XX (Dr Sahel) and Conservatoire National des Arts et Métiers (Dr Berdeaux), Paris, France; Department of Ophthalmology, University of Udine, Udine, Italy (Dr Bandello); Augenklinik, Karlsruhe, Germany (Dr Augustin); Aremis Consultants, Neuilly-sur-Seine, France (Ms Maurel); PBE Consulting, Verona, Italy (Ms Negrini); and Alcon France, Rueil-Malmaison, France (Dr Berdeaux).



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2007 American Medical Association. All Rights Reserved.